We are live on
!
Find out more
SGH
Sivik Global Healthcare Portfolio holdings
AUM
$132M
1-Year Est. Return
24.1%
This Fund
S&P 500
This Quarter
Est. Return
-2.58%
1 Year Est. Return
+24.1%
3 Year Est. Return
+53.78%
5 Year Est. Return
+97.1%
10 Year Est. Return
+690.63%
AUM
$210M
AUM Growth
+$11.3M
(+5.7%)
Cap. Flow
+$16.9M
Cap. Flow
% of AUM
8.06%
Top 10 Holdings %
Top 10 Hldgs %
36.19%
Holding
69
New
21
Increased
12
Reduced
17
Closed
15
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
iShares Biotechnology ETF
IBB
|
+$9.56M |
| 2 |
Bristol-Myers Squibb
BMY
|
+$6.83M |
| 3 |
Elevance Health
ELV
|
+$6.69M |
| 4 |
Gilead Sciences
GILD
|
+$5.95M |
| 5 |
McKesson
MCK
|
+$5.15M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Zimmer Biomet
ZBH
|
+$7.8M |
| 2 |
Amgen
AMGN
|
+$7.51M |
| 3 |
Medtronic
MDT
|
+$5.62M |
| 4 |
GSK
GSK
|
+$5.39M |
| 5 |
Eli Lilly
LLY
|
+$5.21M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 83.15% |
| 2 | Financials | 3.55% |
| 3 | Industrials | 1.31% |
| 4 | Consumer Staples | 0.98% |
| 5 | Energy | 0.76% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
26
Universal Health Services
UHS
$9.96B
| $3.72M | 1.78% |
+35,000
| New | +$4.14M |
|
|
GWPH
27
DELISTED
GW Pharmaceuticals Plc American Depositary Shares
GWPH
| $3.1M | 1.48% |
27,700
| – | – |
|
28
Henry Schein
HSIC
$9.93B
| $3.02M | 1.44% |
+50,750
| New | +$3.06M |
|
29
Vertex Pharmaceuticals
VRTX
$134B
| $2.95M | 1.41% |
40,000
-10,000
| -20% | -$814K |
|
30
Thermo Fisher Scientific
TMO
$222B
| $2.82M | 1.35% |
20,000
-10,000
| -33% | -$1.47M |
|
31
ResMed
RMD
$32.2B
| $2.79M | 1.33% |
+45,000
| New | +$2.76M |
|
|
VWR
32
DELISTED
VWR Corporation
VWR
| $2.75M | 1.31% |
+110,000
| New | +$2.92M |
|
33
Smith & Nephew
SNN
$12.6B
| $2.56M | 1.22% |
85,000
+10,000
| +13% | +$294K |
|
34
Chemed
CHE
$7.09B
| $2.41M | 1.15% |
15,000
| – | – |
|
35
Idexx Laboratories
IDXX
$46.5B
| $2.35M | 1.12% |
+20,000
| New | +$2.28M |
|
36
Dentsply Sirona
XRAY
$2.33B
| $2.31M | 1.1% |
+40,000
| New | +$2.36M |
|
|
37
Eli Lilly
LLY
$1.09T
| $2.21M | 1.05% |
30,000
-70,000
| -70% | -$5.21M |
|
|
WOOF
38
DELISTED
VCA Inc.
WOOF
| $2.06M | 0.98% |
+30,000
| New | +$1.96M |
|
39
Acadia Pharmaceuticals
ACAD
$5.09B
| $2.02M | 0.96% |
70,000
+4,423
| +7% | +$117K |
|
|
PRXL
40
DELISTED
Parexel International Corp
PRXL
| $1.97M | 0.94% |
+30,000
| New | +$1.88M |
|
41
Intuitive Surgical
ISRG
$141B
| $1.9M | 0.91% |
+27,000
| New | +$1.99M |
|
|
WMGI
42
DELISTED
Wright Medical Group Inc
WMGI
| $1.61M | 0.77% |
70,000
-45,000
| -39% | -$1.05M |
|
|
HOLX
43
DELISTED
Hologic
HOLX
| $1.6M | 0.77% |
+40,000
| New | +$1.54M |
|
|
LHCG
44
DELISTED
LHC Group LLC
LHCG
| $1.6M | 0.76% |
35,000
-10,000
| -22% | -$407K |
|
45
Agilent Technologies
A
$42.3B
| $1.59M | 0.76% |
35,000
-35,000
| -50% | -$1.59M |
|
46
Edwards Lifesciences
EW
$53.6B
| $1.41M | 0.67% |
+45,000
| New | +$1.46M |
|
|
IPXL
47
DELISTED
Impax Laboratories, Inc.
IPXL
| $1.39M | 0.66% |
105,000
-25,000
| -19% | -$427K |
|
|
SAGE
48
DELISTED
Sage Therapeutics
SAGE
| $1.02M | 0.49% |
+20,000
| New | +$943K |
|
49
Neurocrine Biosciences
NBIX
$16.6B
| $968K | 0.46% |
25,000
+9,400
| +60% | +$426K |
|
|
BLUE
50
DELISTED
bluebird bio
BLUE
| $926K | 0.44% |
1,158
-206
| -15% | -$164K |
|
Similar funds
AFP
TCPW
GCM
PCGDR
ACM
EWP
9C
STFP
Sivik Global Healthcare's Q4 2016 Portfolio in Review
As of Q4 2016, Sivik Global Healthcare held 69 positions worth $210M, up 5.7% from $198M the previous quarter. Its ten largest holdings account for 36% of the portfolio.
Sivik Global Healthcare deployed $16.9M of net new capital in Q4 2016, opening 21 new positions and adding to 12 existing holdings. Its largest new stake was iShares Biotechnology ETF: 105,000 shares worth $9.29M.
By sector, the portfolio is most concentrated in Healthcare at 83% of assets, down from 91% a quarter earlier, followed by Financials and Industrials.
On the sell side, the largest reduction was Eli Lilly, an estimated $5.21M trimmed.
- Sivik Global Healthcare's largest Q4 2016 buy was iShares Biotechnology ETF: 105,000 shares worth $9.29M.
- Sivik Global Healthcare added most to Aetna Inc in Q4 2016, an estimated $2.39M increase.
- Sivik Global Healthcare's biggest Q4 2016 reduction was Eli Lilly, cutting an estimated $5.21M.
- Sivik Global Healthcare fully exited Zimmer Biomet in Q4 2016, selling an estimated $7.8M.
- Sivik Global Healthcare's ten largest holdings make up 36% of its $210M portfolio in Q4 2016.
- Sivik Global Healthcare opened 21 new positions and closed 15 in Q4 2016.
- Sivik Global Healthcare's portfolio value rose 5.7% quarter-over-quarter to $210M.
Based on Sivik Global Healthcare's 13F filing for Q4 2016, filed 13 Feb 2017.